Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Cosmos Health signs LOI to acquire Doc Pharma S.A.
-
Cosmos Health secures additional 180-day Nasdaq extension to regain compliance.
-
Cosmos Health secures a 3-year contract manufacturing agreement for 3.9 million units of VASCLOR GEST progesterone pessaries.
-
Cosmos Health CEO issues letter to shareholders.
-
Cosmos Health inaugurates state-of-the-art capsule production line and secures new 5-year contract manufacturing agreement for 385,000 units
-
Cosmos Health acquires international patent application WO2025108566A1 and expands nanotechnology initiatives.
-
Cosmos Health launches Oliv18™, a USDA and EU certified whole olive polyphenol supplement targeting cardiovascular and antioxidant categories.
-
Sky Premium Life is now available for shipment across all 27 European Union Member States through Skroutz.
-
Cosmos Health identifies approximately $20 million in non-core assets available for monetization to accelerate growth and unlock shareholder value.
-
Cosmos Health provides balance sheet update and notes no known business reason for reason for recent share price decline. Reaffirms growth outlook.